Completed PHASE2 INTERVENTIONAL 1-arm NCT00068419

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy

Sponsor: Children's Oncology Group

Conditions Desmoid Tumor

Interventions laboratory biomarker analysis sulindac tamoxifen citrate

Updated 8 times since 2017 Last updated: Feb 7, 2020 Started: Feb 29, 2004 Primary completion: Apr 26, 2010 Completion: Apr 26, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Desmoid Tumor, this trial is completed. The trial is conducted by Children's Oncology Group and has accumulated 8 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2
Apr 2019 — Mar 2020 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Oncology Group
National Cancer Institute (NCI)

Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Monrovia, United States